Rose Gelineau-Morel

Rose Gelineau-Morel

Auto-generated profile, based on publicly available information

Rose Gelineau-Morel

Department of Pediatrics University of Missouri‐Kansas City School of Medicine Kansas City MO

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Journal of Child Neurology
Verified
Journal Article
Closed access
RGRose Gelineau-Morel
Rose Gelineau-Morel
MKMichael C. Kruer
Michael C. Kruer
JGJordan F. Garris
Jordan F. Garris
ALAmal Abu Libdeh
Amal Abu Libdeh
DBDaniel A. N. Barbosa
Daniel A. N. Barbosa
JOJennifer A. O’malley
Jennifer A. O’malley
Deep brain stimulation (DBS) is an established intervention for use in pediatric movement disorders, especially dystonia. Although multiple publications have provided guidelines for deep brain stimulation patient selection and programming in adults, there are no evidence-based or consensus statements published for pediatrics. The result is lack of standardized care and underutilization of this effective treatment. To this end, we assembled a focus group of 13 pediatric movement disorder specialists and 1 neurosurgeon experienced in pediatric deep brain stimulation to review recent literature and current practices and propose a standardized approach to candidate selection, implantation target site selection, and programming algorithms. For pediatric dystonia, we provide algorithms for (1) programming for initial session and follow-up sessions, and (2) troubleshooting side effects encountered during programming. We discuss common side effects, how they present, and recommendations for management. This topical review serves as a resource for movement disorders specialists interested in using deep brain stimulation for pediatric dystonia.

9 September 2023 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
RGRose Gelineau-Morel
Rose Gelineau-Morel
FUFatima Usman
Fatima Usman
SSSaadatu Shehu
Saadatu Shehu
HYHung-Wen Yeh
Hung-Wen Yeh
MSMohammad A. Suwaid
Mohammad A. Suwaid
ZFZubaida L. Farouk
Zubaida L. Farouk

1 June 2021 in Pediatric Neurology
Verified
Journal Article
Closed access
RGRose Gelineau-Morel
Rose Gelineau-Morel
JDJennifer Dilts
Jennifer Dilts

10 March 2025 in Annals of Neurology
Verified
Journal Article
Closed access
RGRose Gelineau‐Morel
Rose Gelineau‐Morel
NDNomazulu Dlamini
Nomazulu Dlamini
JBJoel Bruss
Joel Bruss
ACAlexander L. Cohen
Alexander L. Cohen
ARAmanda Robertson
Amanda Robertson
ABAaron D. Boes
Aaron D. Boes

3 July 2025 in Annals of Neurology
Verified
Journal Article
Closed access
KGKat Gemperli
Kat Gemperli
XLXinguo Lu
Xinguo Lu
KCKeerthana Chintalapati
Keerthana Chintalapati
ARAlyssa Rust
Alyssa Rust
RBRishabh Bajpai
Rishabh Bajpai
BABhooma R. Aravamuthan
Bhooma R. Aravamuthan

31 January 2022 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
JDJoseph S. Domino
Joseph S. Domino
RGRose Gelineau-Morel
Rose Gelineau-Morel
CKChristian Kaufman
Christian Kaufman
Cockayne syndrome (CS) is a rare progeroid disorder characterized by multisystem degeneration, including neurological dysfunction, for which deep brain stimulation (DBS) is a proposed treatment. This study represents only the third case of DBS for CS-associated movement disorder and the first in which both proposed targets had devices implanted, allowing for direct comparison. A case of DBS for CS-associated movement disorder is presented. Previous literature documents two cases with one targeting the ventral intermediate nucleus of the thalamus (VIM) and the other targeting the globus pallidus interna (GPi). Our patient underwent stimulation of GPi nuclei followed by repositioning to VIM nuclei with improved symptom control using VIM stimulation. In all cases, there was a significant clinical benefit without off-target effects. CS-associated movement disorder exhibits phenotypic variability for which DBS is a viable treatment. Target selection should be driven by clinical phenotype.